Is Fibroadipose Tissue Cancer? Defining the Health Risks

Fibroadipose tissue is not cancer. The term describes a mix of fibrous (connective) and adipose (fatty) tissue that can appear throughout the body in a wide range of medical situations, the vast majority of which are benign. Confusion arises because fibroadipose tissue sometimes shows up on imaging reports, in pathology descriptions of tumors, or in the context of genetic conditions that share certain mutations with cancers. Understanding where and why this tissue appears, and what it actually signals about your health, requires looking at several distinct medical scenarios.

What Fibroadipose Tissue Actually Is

Your body naturally contains both fibrous tissue (the collagen-rich connective material that forms tendons, scar tissue, and structural scaffolding) and adipose tissue (fat cells that store energy and cushion organs). When the two grow together in an area where they normally would not dominate, clinicians call the resulting mass or deposit “fibroadipose” tissue. This can happen through injury repair, chronic inflammation, genetic conditions, or simply as part of aging. The tissue itself is composed of ordinary cell types doing ordinary things in an unusual location or in unusual proportions.

On its own, fibroadipose tissue has no inherent tendency to become cancerous. It lacks the hallmarks of malignancy: uncontrolled cell division, invasion of surrounding structures, and the ability to spread to distant organs. That said, the contexts in which fibroadipose tissue appears vary enormously in their seriousness, from a harmless incidental finding on a scan to a debilitating vascular anomaly in a child’s leg. The tissue is best understood not as a single diagnosis but as a descriptive label that can appear across many different conditions.

Fibro-Adipose Vascular Anomaly (FAVA)

One condition that puts fibroadipose tissue front and center is FAVA, a complex vascular malformation typically found in children and young adults. FAVA involves an abnormal tangle of blood vessels embedded within fibroadipose tissue, usually deep inside a muscle of a limb. It is classified as a benign lesion, not a cancer, but it can be intensely painful and functionally disabling. Patients often develop joint contractures and chronic pain that interferes with walking or daily activities.

FAVA was only formally described in the medical literature relatively recently and is thought to be underrecognized. A study of 75 cases found that about 70% harbored somatic mutations in the PIK3CA gene, which encodes a component of a cell-signaling pathway involved in growth and survival.¹ That same gene is mutated in certain cancers, which understandably alarms patients and families who encounter the term. But the mutation in FAVA is somatic and mosaic, meaning it arose after conception in a small population of cells and is not inherited or systemic. A separate study found no significant link between the presence of PIK3CA mutations and the clinical severity of FAVA, suggesting that this gene is not necessarily the sole driver of the condition.²

The critical point is that sharing a mutation with cancer does not make something cancer. Many benign growths and developmental anomalies carry mutations in genes that are also implicated in malignancies. What distinguishes cancer is the behavior of the cells: their capacity for invasion, metastasis, and progressive destruction of normal tissue. FAVA lesions are slow-flow vascular malformations with specific characteristics that do not include these hallmarks.³

PIK3CA-Related Overgrowth Conditions

FAVA belongs to a broader family of disorders known as PIK3CA-related overgrowth spectrum (PROS). These conditions all involve mosaic activating mutations in PIK3CA that cause localized tissue overgrowth. Some patients develop segmental overgrowth of fibroadipose tissue, bone, or a combination, sometimes in patterns that overlap with older diagnoses like Proteus syndrome or CLOVES syndrome. A study that performed exome sequencing on affected versus unaffected tissue from individuals with these overgrowth syndromes identified cancer-associated PIK3CA mutations (specifically, changes at position His1047) in nine out of ten patients tested.⁴

Despite carrying mutations found in breast, colon, and other cancers, these overgrowth conditions are not themselves cancerous. The overgrown tissue remains structurally organized and does not metastasize. However, clinicians do monitor these patients, partly because the theoretical risk of a “second hit” mutation in the same pathway could elevate cancer susceptibility over a lifetime. Newer targeted therapies, particularly the selective PI3K-alpha inhibitor alpelisib, have shown reductions in lesion burden and functional improvements in PROS patients, though long-term risk assessment is still ongoing.⁵

Lipomas, Fibrolipomas, and the Liposarcoma Question

Another common scenario where fibroadipose tissue appears is in lipomas and fibrolipomas. A lipoma is a benign, slow-growing lump of fat cells that forms under the skin or within muscle. When the lipoma contains a significant fibrous component, it may be called a fibrolipoma. These are among the most common soft-tissue tumors in adults, and the overwhelming majority never become dangerous. Treatment is straightforward surgical excision, which is associated with a very low recurrence rate.⁶

The worry that brings many patients to a search engine, though, is whether a fatty lump could be or could become a liposarcoma, which is a genuine cancer of fat cells. The honest answer is that transformation from an ordinary lipoma to a liposarcoma is considered extremely rare. A case report has noted that surgical excision of giant lipomas is recommended partly due to the theoretical risk of sarcomatous change, but the evidence for this actually happening in a typical small lipoma is thin.⁷ In practice, the bigger diagnostic challenge is telling a lipoma apart from a well-differentiated liposarcoma (also called an atypical lipomatous tumor), because the two can look similar on imaging and even under the microscope.

The key molecular distinguishing feature is amplification of the MDM2 gene. In a study of 86 tumors initially classified as lipomas, 98% showed normal MDM2 levels. The two that had MDM2 amplification were reclassified as atypical lipomatous tumors upon closer review.⁸ Research has also found that MDM2 amplification is associated with malignancy and dedifferentiation in liposarcomas, making it a reliable marker to distinguish benign lipomas from their malignant mimics.⁹

Even atypical lipomatous tumors, the lowest-grade malignancies of fatty tissue, tend to behave relatively well when removed with adequate margins. A study of these tumors in the extremities and trunk wall found five-year local recurrence-free survival above 80% after marginal surgical resection, and no distant metastases were observed in any case.¹⁰ That said, a small number of atypical lipomatous tumors can dedifferentiate into higher-grade sarcomas, which is why follow-up imaging is typically recommended.

How Imaging Can Create Confusion

Modern imaging, especially MRI, is excellent at detecting fatty tissue. When a radiologist reports a mass containing both fat and fibrous tissue, the description alone does not tell you whether you are looking at something benign or concerning. The radiologic differences between benign and malignant lipomatous lesions can be subtle, and pathologic correlation through biopsy is often needed to settle the question.¹¹

Certain imaging features raise suspicion: thick internal septa, nodular non-fatty components, areas that enhance strongly with contrast, and large size (typically above 10 cm). But a straightforward fatty mass with thin septa and no solid components is almost always a benign lipoma. If you have received an imaging report that mentions fibroadipose tissue or a lipomatous lesion and you are uncertain what it means, asking your doctor whether the features are reassuring or whether biopsy is warranted is always reasonable. For most patients, the answer will be reassuring.

Fibrofatty Replacement in the Heart

Fibroadipose tissue also appears in an entirely different medical context: a heart condition called arrhythmogenic right ventricular cardiomyopathy (ARVC). In ARVC, heart muscle cells are progressively replaced by fibrofatty tissue due to inherited genetic mutations. This replacement disrupts the heart’s electrical conduction, causing dangerous arrhythmias and, in some cases, sudden cardiac death.¹²

ARVC primarily affects the right ventricle, but fibrofatty changes are found in the left ventricle in the vast majority of cases examined at autopsy. One large multicenter autopsy study of 202 ARVC hearts found left ventricular involvement in 87% of cases.¹³ The fibrofatty tissue in ARVC is a hallmark of disease, characterized by inflammation and progressive loss of functioning muscle cells.¹⁴

This is clearly not cancer, but it is not harmless either. ARVC is a serious inherited condition that requires ongoing cardiac monitoring, lifestyle modification (often including restriction of competitive sports), and sometimes an implantable defibrillator. The fibrofatty tissue in this context is a consequence of the disease process, not a cause of it, and it does not have any malignant potential.

Fibroadipose Tissue in Muscle Degeneration

When skeletal muscle is chronically damaged or weakened, whether from muscular dystrophy, aging, or prolonged disuse, the body’s repair mechanisms can go awry. Instead of regenerating functional muscle fibers, the damaged area may be gradually filled with fat and fibrous tissue. This process is driven by cells called fibro-adipogenic precursors, which normally support muscle regeneration but, under conditions of persistent damage and inflammation, differentiate into fat cells and fibroblasts instead.¹⁵

In muscular dystrophies, the progressive loss of muscle fibers and their replacement by fat and connective tissue is a defining feature of the disease. The resulting weakness reflects the loss of functional muscle tissue itself, not any threat from the replacement tissue becoming malignant. The fibroadipose infiltration in degenerating muscle is a sign of lost regenerative capacity, not a precursor to cancer. Similar age-related fatty infiltration of muscles (sometimes visible on imaging as “marbling” within a muscle) is common in older adults and relates to frailty and functional decline rather than to any tumor risk.

Breast Tissue Composition and Cancer Risk

One area where fibroadipose tissue intersects with cancer risk, though not through any direct transformation, is breast health. The breast is naturally composed of glandular (dense) tissue and fatty tissue, and their relative proportions vary among individuals. Mammographic density, the ratio of dense to fatty tissue seen on a mammogram, is a well-established risk factor for breast cancer. But the relationship is more nuanced than “dense breasts are dangerous.”

A study found that large areas of both dense tissue and fat tissue were independently associated with higher breast cancer risk. Women with the most dense tissue had about 2.8 times the odds of breast cancer compared to those with the least, while women with the most fat tissue had about 2.4 times the odds. The highest risk was found in women who had large amounts of both.¹⁶ Further research has shown that the spatial arrangement of these tissue types within the breast also matters. The way fatty and dense tissue are organized relative to each other carries predictive information about cancer risk beyond what simple density measurements capture.¹⁷

It is worth emphasizing that the fibroadipose tissue in the breast is not “pre-cancerous” in any way. The relationship is statistical, not causal in the way a precancerous lesion causes cancer. Breast tissue composition affects how easily cancers can be detected on imaging and may reflect underlying hormonal and growth-factor environments that influence cancer development, but the fat and fibrous tissue themselves are not transforming into cancer cells.

Treating FAVA and Related Conditions

For patients diagnosed with FAVA, treatment has evolved considerably. Because FAVA lesions infiltrate muscle tissue, complete surgical removal is often impossible without significant functional loss. This has driven interest in medical therapy, particularly sirolimus (also known as rapamycin), a drug that inhibits the mTOR pathway, which sits downstream of the PIK3CA signaling abnormality found in many FAVA cases.

In a study of eight FAVA patients treated with sirolimus, the drug softened masses and produced measurable shrinkage within roughly two to ten weeks. All seven patients who reported pain experienced relief within a few weeks. Five patients achieved a complete response, and three had a partial response.¹⁸ Earlier case reports also documented rapid, dramatic improvement in pain and quality of life with sirolimus.¹⁹

A caveat worth knowing: lesions may return after stopping the medication, which means some patients need long-term low-dose maintenance therapy.²⁰ For patients in the broader PIK3CA-related overgrowth spectrum, the targeted drug alpelisib represents a newer therapeutic option that acts more specifically on the mutant PI3K-alpha enzyme, though long-term data are still accumulating.⁵

When Fibroadipose Findings Actually Warrant Concern

Given how many benign situations produce fibroadipose tissue, it is fair to ask: when should you actually be worried? A few general principles help:

• Size and growth: A fatty mass that is rapidly enlarging, especially if it is deep-seated or larger than about 5 cm, deserves imaging and possibly biopsy. Most lipomas grow slowly or not at all.
• Non-fatty components: If imaging shows thick septa, solid nodular areas, or strong contrast enhancement within an otherwise fatty mass, the concern for an atypical lipomatous tumor or liposarcoma goes up. MRI is particularly useful for evaluating these features, though pathologic confirmation through biopsy remains the gold standard.
• Location: Deep intramuscular fatty tumors carry a slightly higher statistical likelihood of being atypical lipomatous tumors compared to superficial subcutaneous lumps. Retroperitoneal fatty tumors (those behind the abdominal organs) deserve particular attention because well-differentiated liposarcomas in that location are harder to completely excise and can behave more aggressively over time.
• Pain: Most lipomas are painless. A painful fatty mass, particularly in a young person’s limb, may point toward FAVA or another vascular anomaly rather than a simple lipoma.

For the majority of people who encounter the term “fibroadipose” on an imaging report or pathology result, the finding reflects one of the many non-cancerous processes described above. The tissue itself is ordinary. What matters is the clinical context: where it is, how it behaves, and whether any features suggest something beyond a benign process. If you are unsure, asking your physician whether the specific imaging characteristics or pathology findings in your case warrant further investigation is the most productive next step.